- Home
- CVM vs EQ Comparison
CVM vs EQ Comparison
Compare CVM & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVM
- EQ
- Stock Information
- Founded
- CVM 1983
- EQ 2017
- Country
- CVM United States
- EQ United States
- Employees
- CVM N/A
- EQ N/A
- Industry
- CVM Biotechnology: Biological Products (No Diagnostic Substances)
- EQ Biotechnology: Pharmaceutical Preparations
- Sector
- CVM Health Care
- EQ Health Care
- Exchange
- CVM Nasdaq
- EQ Nasdaq
- Market Cap
- CVM 71.2M
- EQ 67.9M
- IPO Year
- CVM 1987
- EQ 2018
- Fundamental
- Price
- CVM $10.03
- EQ $1.87
- Analyst Decision
- CVM
- EQ Hold
- Analyst Count
- CVM 0
- EQ 2
- Target Price
- CVM N/A
- EQ $1.00
- AVG Volume (30 Days)
- CVM 303.9K
- EQ 3.1M
- Earning Date
- CVM 08-14-2025
- EQ 11-12-2025
- Dividend Yield
- CVM N/A
- EQ N/A
- EPS Growth
- CVM N/A
- EQ N/A
- EPS
- CVM N/A
- EQ N/A
- Revenue
- CVM N/A
- EQ $16,553,000.00
- Revenue This Year
- CVM N/A
- EQ N/A
- Revenue Next Year
- CVM N/A
- EQ N/A
- P/E Ratio
- CVM N/A
- EQ N/A
- Revenue Growth
- CVM N/A
- EQ N/A
- 52 Week Low
- CVM $1.98
- EQ $0.27
- 52 Week High
- CVM $39.30
- EQ $2.35
- Technical
- Relative Strength Index (RSI)
- CVM 52.57
- EQ 64.22
- Support Level
- CVM $9.58
- EQ $1.78
- Resistance Level
- CVM $12.68
- EQ $2.35
- Average True Range (ATR)
- CVM 1.30
- EQ 0.30
- MACD
- CVM -0.28
- EQ -0.03
- Stochastic Oscillator
- CVM 28.57
- EQ 43.53
About CVM Cel-Sci Corporation
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development of the treatment of cancer and other diseases using the immune system. The Company's core capabilities include drug discovery, research, development, and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.
About EQ Equillium Inc.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.